Skip to main content
. 2015 Jan 13;19(3):608–619. doi: 10.1111/jcmm.12445

Fig 5.

Fig 5

The STAT3/c-Myc pathway mediates miR-16 down-regulation during cardiac hypertrophy. (A) Activation of STAT3 and c-Myc in myocardial hypertrophy in rats receiving AAC treatment for 2 weeks (n + 5–7). (B) Activation of STAT3 and c-Myc in PE-treated NRVCs (n + 3). (C) miR-16 and ANP mRNA expressions were assessed by qRT-PCR assay in PE-treated NRVCs without and with the presence of STAT3 inhibitor cryptotanshinone (10 μM) and c-Myc inhibitor 10058-F4 (30 μM), respectively (n + 3). Data are shown as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001.